We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+6.36%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$123M
AUM Growth
-$5.11M
Cap. Flow
-$4.27M
Cap. Flow %
-3.48%
Top 10 Hldgs %
68.23%
Holding
60
New
2
Increased
7
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
DCGO icon
DocGo
DCGO
+$1.17M
2
CHRS icon
Coherus Oncology
CHRS
+$394K
3
AXSM icon
Axsome Therapeutics
AXSM
+$336K
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$248K
5
AXDX
Accelerate Diagnostics
AXDX
+$158K

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$5.57M
2
CYTK icon
Cytokinetics
CYTK
+$1.16M
3
LQDA icon
Liquidia Corp
LQDA
+$139K

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Energy 5.73%
3 Consumer Staples 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$123B
$38.2M 31.1%
703,606
+1,308
+0.2% +$66.6K
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.4B
$10.7M 8.68%
77,240
– –
BDSX icon
3
Biodesix
BDSX
$205M
$7.63M 6.22%
267,414
– –
ELUT icon
4
Elutia
ELUT
$41.1M
$5.21M 4.25%
1,655,184
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.3B
$4.63M 3.77%
250,400
+10,000
+4% +$248K
OVV icon
6
Ovintiv
OVV
$16.2B
$4.37M 3.56%
84,200
– –
PRTA icon
7
Prothena Corp
PRTA
$454M
$4.2M 3.42%
169,574
– –
QDEL icon
8
QuidelOrtho
QDEL
$1.13B
$3.13M 2.55%
65,203
– –
SILK
9
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$2.9M 2.36%
158,094
– –
STOK icon
10
Stoke Therapeutics
STOK
$1.72B
$2.83M 2.31%
210,000
– –
PHR icon
11
Phreesia
PHR
$660M
$2.74M 2.24%
114,700
– –
UTHR icon
12
United Therapeutics
UTHR
$22.5B
$2.53M 2.06%
11,000
– –
MASI
13
DELISTED
Masimo
MASI
$2.24M 1.83%
15,280
– –
FHTX icon
14
Foghorn Therapeutics
FHTX
$305M
$2.15M 1.76%
320,930
– –
HROW icon
15
Harrow
HROW
$1.66B
$1.98M 1.62%
150,000
– –
DCGO icon
16
DocGo
DCGO
$66.2M
$1.86M 1.51%
460,000
+310,000
+207% +$1.17M
INBX
17
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.69M 1.38%
48,448
– –
ETRN
18
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.66M 1.35%
133,050
– –
AXGN icon
19
Axogen
AXGN
$2.1B
$1.4M 1.14%
173,000
– –
PTGX icon
20
Protagonist Therapeutics
PTGX
$8.64B
$1.39M 1.13%
48,000
– –
ALKS icon
21
Alkermes
ALKS
$8.62B
$1.35M 1.1%
50,000
– –
CORT icon
22
Corcept Therapeutics
CORT
$9.83B
$1.26M 1.03%
50,000
– –
ATEC icon
23
Alphatec Holdings
ATEC
$1.27B
$1.21M 0.99%
88,000
– –
TXG icon
24
10x Genomics
TXG
$5.49B
$1.13M 0.92%
30,000
– –
APLS
25
DELISTED
Apellis Pharmaceuticals
APLS
$1.06M 0.86%
18,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Birchview Capital held 60 positions worth $123M, down 4% from $128M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Birchview Capital withdrew a net $4.27M in Q1 2024, closing 1 position and reducing 2 holdings. Its most notable exit was Immunogen Inc, an estimated $5.57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Energy and Consumer Staples.

Against the trend, Birchview Capital opened a new position in Axsome Therapeutics worth $319K.

  • Birchview Capital's largest Q1 2024 buy was Axsome Therapeutics: 4,000 shares worth $319K.
  • Birchview Capital added most to DocGo in Q1 2024, an estimated $1.17M increase.
  • Birchview Capital's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $1.16M.
  • Birchview Capital fully exited Immunogen Inc in Q1 2024, selling an estimated $5.57M.
  • Birchview Capital's ten largest holdings make up 68% of its $123M portfolio in Q1 2024.
  • Birchview Capital opened 2 new positions and closed 1 in Q1 2024.
  • Birchview Capital's portfolio value fell 4% quarter-over-quarter to $123M.

Based on Birchview Capital's 13F filing for Q1 2024, filed 14 May 2024.